Bowery Valuation logo

Bowery Valuation

The first tech-enabled commercial appraisal firm

109 employees · est. 2016 · New York, United States

VS
MYCB1 Group B.V. logo

MYCB1 Group B.V.

MYCB1 Group B.V. produces, and distributes GMP-grade cannabinoid medicines via its German subsidiary, MYCB1 GmbH

18 employees · est. 2017 · Amsterdam, The Netherlands

Bowery Valuation is the older company (2016 vs 2017); Bowery Valuation is the larger of the two.

Side-by-Side Comparison

Bowery Valuation MYCB1 Group B.V.
Founded
2016 older 2017
Headquarters
New York, United States Amsterdam, The Netherlands
Employees
109 larger 18
Industry
Productivity, Real Estate, SaaS AI, Health Care, Medical Devices
Funding Stage
Series B Debt Financing
Total Funding
$78.05M $3.11M
Funding Rounds
7 3
Services
Not tracked yet regulatory infrastructure support, GMP/GDP operations, storage services, distribution services, brand retention services, curated product portfolio
Target Customers
Not tracked yet pharmaceutical companies, cannabis brands, healthcare distributors
Taxonomy
Commercial Appraisal, Tech-enabled Appraisal, Big Data, Advanced Technology, Proprietary Platform, Venture Capital-backed, Cloud-based Software, Mobile Application, Appraisal Reports, Natural Language Generator Cannabinoid Medicines, GMP-grade Pharmaceuticals, Pharmaceutical Manufacturing, Prescription-only Medications, Personalized Medicine, Digital Health Solutions, Generative AI, Real-World Evidence, Patient-Centric Healthcare, Data-Driven Health Decisions, Health Technology Scale-up, Evidence-Based Healthcare, Software Engineering In Health, Pharmacy Operations
Website
boweryvaluation.com mycb1.de
Bowery Valuation logo

About Bowery Valuation

Bowery Valuation is redefining the commercial appraisal space through big data, advanced technology, and extensive expertise. Their proprietary platform allows appraisers to work smarter and faster, delivering unparalleled accuracy and consistency in record time. Founded in 2016, Bowery has position...

MYCB1 Group B.V. logo

About MYCB1 Group B.V.

MYCB1 Group B.V. is a Dutch pharmaceutical group that stands out for its specialization in cannabinoid-based medical solutions. Its subsidiary, MYCB1 GmbH in Steinheim, Westphalia, serves as the core of its operations, focusing on the production and distribution of GMP-grade cannabinoid medicines....

We will tell you when either one moves

BounceWatch watches Bowery Valuation and MYCB1 Group B.V. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Bowery Valuation and MYCB1 Group B.V. — by email.

Frequently Asked Questions

Bowery Valuation — The first tech-enabled commercial appraisal firm. MYCB1 Group B.V. — MYCB1 Group B.V. produces, and distributes GMP-grade cannabinoid medicines via its German subsidiary, MYCB1 GmbH . Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Bowery Valuation has raised $78.05M while MYCB1 Group B.V. has raised $3.11M.
Bowery Valuation and MYCB1 Group B.V. operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Bowery Valuation with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Bowery Valuation on 11 Sep 2024, and MYCB1 Group B.V. on 18 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy